Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2010 Nov;117(11):2152-61.e1-2. doi: 10.1016/j.ophtha.2010.03.031. Epub 2010 Jul 29.

Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.

Collaborators (462)

Lewis RA, Bourg JM, Fainstein V, Krason Z, Morales JF, Orengo-Nania S, Samo TC, Spencer S, Weikert MP, Allen RC, Frady P, Gross R, Schmidt A, Shawver L, Shigley J, Slight B, Sotuyo R, Travers S, Srivastava SK, Gibbs A, Gibbs D, Jordan D, Myles B, Rutter J, Capone A Jr, Furukuwa D, Hubbard B, Martin DF, Goldman M, Brown J, Ciulla T, Craft J, Danis R, Fry P, Gao H, Gupta S, Hernandez J, Poe D, Pratt L, Richardson JD, Steffens T, Wheat LJ, Zwickl B, Dunn JP, Brown DM, Cain D, Emmert D, Herring M, Jacobowitz A, Leder HA, Livingston AG, Morton Y, Nolan KD, Semba RD, Soto P, Thorne JE, Barditch-Crovo P, Bélair ML, Bolton SG, Brodine JB, Brune LM, Galor A, Jabs DA, Kapoor M, Kedhar SR, Kempen JH, Kim SJ, Oliver AL, Peters GB 3rd, Stevenson R, Tarver-Carr M, Wittenberg S, Wang S, Bergsma D, Clark R, Cooper R, Elison J, Fuller B, Jarrott C, Otillio L, Reinoso M, Romero C, Barron B, Bye R, Conway M, Dillon L, Lombard A, Peyman G, Rescigno R, Bhagat N, Paez-Boham R, Paez-Quinde M, Heinemann MH, Coleman S, Daniel S, Janis R, Khanifer A, Kozbial A, Rivera DI, Sepkowitz K, Boyd K, Chan RV, Chiu C, Cole C, Doering C, Elison J, Lee S, Lu F, Murphy J, Pachydaki S, Peroni C, Rahhal FM, Reddy A, Warden S, Friedberg DN, Addessi A, Dieterich D, Lorenzo-Latkany M, Pei MP, McMeeking A, Lyon AT, Ackatz L, Gill M, Kaminski L, Mirza R, Murphy R, Palella F, Ramirez C, Rozenbajgier Z, Ryan D, Evica Simjanoski E, Habib A, Koecher J, Mathura J, Muñana A, Shankle J, Weinberg DV, Yuhr J, MacCumber MW, Gaynes B, Giannoulis C, Hulvey P, Kessler H, Khan HS, Kopp A, Merrill P, Morini F, Smith N, Tenorio A, Voskuil-Marre D, Woo K, Kuppermann BD, Alexandiescu B, Forthal DN, Grijalva J, Jehan F, Lopez K, Magallon R, Moinfar N, Trump B, Vega M, Williams R, Holland GN, Almanzor RD, Carlson ME, Castellanos JT, Craddock JA, Gonzales S, Johiro AK, Kalyani PS, Kapamajian MA, LeBeck DL, Lipka KM, Ransome SS, Chafey SA, Charonis AC, Kappel PJ, Moe AA, Piñón G, Sanderson A, Shah KH, Stalling R, Thayer D, Vaudaux JD, Freeman WR, Cochran D, Kozak I, Loughran M, Magana L, Morrison V, Nguyen V, Oster S, Chaidhawanqual S, Cheng L, Clark T, Cleveland M, Gannon RL, Garcia C, Goldberg D, Hedaya J, Karavellas M, Kemper T, Kosobucki B, Mask A, Reagan N, Song MK, Torriani F, Wong D, Young T, Duncan J, Ballesteros F Jr, Bhisitkul R, Brown D, Clay D, Deiner M, Eubank D, Jacobson M, Lew M, Margolis T, Aberg J, Hoffman J, Irvine A, Larson J, Lawrence J, Narahara M, Trinidad M, Meredith TA, Barnhart S, Cantrell D, Garg S, Hartnett E, Landers MB, Moyer S, Wohl D, Betran S, DeBoer K, Eifrig D, Foley J, Jeffries A, Kylstra J, Longmire B, Myers S, N'Dure F, Oh KT, Pantell J, Pedersen S, Rich C, Sotelo CA, Horst Cv, Wadhvania S, Nichols CW, Bardsley M, Devine CC, Kostman J, Maguire A, Nyberg W, Smith L, Helker C, MacGregor R, McGibney K, Mickelberg K, Lim JI, Bhatti R, Canzano J, Chang TS, Charonis A, Chong L, Equi R, Fawzi A, Flaxel C, Garcia J, Klesert T, Kramer F, Levin L, Nichols T, Pelzek C, Podilla M, Richine L, Romo D, Sadda S, Scartozzi R, See R, Shiramizu K, Thomas M, Walonker A, Walsh A, Wu Z, Pavan P, Leto J, Madow B, Oehler R, Patel N, Saxon W, Sherouse S, Burrows A, Carlton S, Goldstein B, Gompf S, Hernandez B, Iyer M, Kelty P, Kramer A, Millard S, Nadler J, Tordilla-Wadia J, Walker N, Davis G, Blem R, Bourg J, Horna J, Kelso C, Krason Z, Li HK, Nguyen LC, Nolen R, Onarato M, Paar D, Rivas S, Seitz V, Spillar H, Uwaydat S, Jabs DA, Hilal Y, Nieves M, Pascual K, Slutsky J, Stevens M, Southall JC, Meinert CL, Ahuja A, Amend-Libercci DA, Collins KL, Collison BJ, Colvin R, Dodge J, Donithan M, Ewing C, Frick K, Holbrook JT, Isaacson MR, Jackson RM, Livingston H, McCaffrey L, Puhan M, Reyes G, Smith J, Smith M, Sugar E, Thorne JE, Tonascia JA, Van Natta ML, Wagoner A, Benham C, Foster G, Harle J, Kaplan Gilpin AM, Kempen JH, Martin BK, Min N, Murrow L, Oziemkowska MJ, Ng WP, Scott PE, Smothers E, West E, Woo C, Wu A, Zong A, Danis R, Chandler C, Gangaputra S, Guilfoil G, Hubbard L, Joyce J, Pauli T, Robinson N, Thayer D, Pak JW, Zhang G, Altaweel M, Armstrong J, Davis MD, Glaeser S, Hughes K, Hurlburt D, Kastorf L, Neider M, Traut T, Vanderhoof-Young M, Wabers H, Kurinij N, Jabs DA, Danis R, Kurinij N, Meinert CL, Thorne JE, Davis MD, Holbrook JT, Jabs DA, Danis R, Dunn JP, Holland GN, Isaccson MR, Jacobson M, Kurinij N, Lewis R, Nolan KD, Meinert CL, Nyberg W, Palella F, Thorne JE, Addessi A, Brune L, Clark R, Clark T, Davis J, Davis MD, Freeman WR, Friedberg D, Gilman J, Holbrook JT, Horna J, Hubbard L, Jacobson M, Martin DF, Meredith TA, Muñana A, Murphy R, Pavan P, Spencer S, Steffens T, Thayer D, van der Horst C, Wallach F, Phair JP, Conway BP, Davis BR, Jabs DA, Kurinij N, Meinert CL, Musch D, Nussenblatt RB, Thorne JE, Whitley R, Brown B Jr, Davis MD, Grizzle J, Hillis A, Holbrook J, Smith H, Tonascia JA, Spencer S, Almanzor RD, Gibbs D, Isaacson M, Lew M, Lewis RA, Ballesteros F, Grijalva J, Lopez K, Neisser LG, Paez-Boham R.

Author information

  • 1Department of Ophthalmology, the Mount Sinai School of Medicine, New York, New York, USA. douglas.jabs@mssm.edu

Abstract

PURPOSE:

To describe the 5-year outcomes of patients with cytomegalovirus (CMV) retinitis and AIDS in the era of highly active antiretroviral therapy (HAART).

DESIGN:

Prospective, multicenter, observational study.

PARTICIPANTS:

A total of 503 patients with AIDS and CMV retinitis.

METHODS:

Follow-up every 3 months with medical history, ophthalmologic examination, laboratory testing, and retinal photographs. Participants were classified as having previously diagnosed CMV retinitis and immune recovery (CD4+ T cells ≥ 100 cells/μl), previously diagnosed retinitis and immune compromise, and newly diagnosed CMV retinitis (diagnosis <45 days before enrollment).

MAIN OUTCOME MEASURES:

Mortality, retinitis progression (movement of the border of a CMV lesion ≥ ½ disc diameter or occurrence of a new lesion), retinal detachment, immune recovery uveitis (IRU), and visual loss (< 20/40 and ≥ 20/200).

RESULTS:

Overall mortality was 9.8 deaths/100 person-years (PY). Rates varied by group at enrollment from 3.0/100 PY for those with previously diagnosed retinitis and immune recovery to 26.1/100 PY for those with newly diagnosed retinitis. The rate of retinitis progression was 7.0/100 PY and varied from 1.4/100 PY for those with previously diagnosed retinitis and immune recovery to 28.0/100 PY for those with newly diagnosed retinitis. The rate of retinal detachment was 2.3/100 eye-years (EY) and varied from 1.2/100 EY for those with previously diagnosed retinitis and immune recovery to 4.9/100 EY for those with newly diagnosed retinitis. The rate of IRU was 1.7/100 PY and varied from 1.3/100 PY for those with previously diagnosed retinitis and immune recovery at enrollment to 3.6/100 PY for those with newly diagnosed retinitis who subsequently experienced immune recovery. The rates of visual loss to < 20/40 and to ≤ 20/200 were 7.9/100 EY and 3.4/100 EY, respectively; they varied from 6.1/100 EY and 2.7/100 EY for those with previously diagnosed retinitis and immune recovery to 11.8/100 EY and 5.1/100 EY for those with newly diagnosed retinitis. Although the event rates tended to decline with time, in general, at no time did they reach zero.

CONCLUSIONS:

Despite the availability of HAART, patients with AIDS and CMV retinitis remain at increased risk for mortality, retinitis progression, complications of the retinitis, and visual loss over a 5-year period.

FINANCIAL DISCLOSURE(S):

Proprietary or commercial disclosure may be found after the references.

Copyright © 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

PMID:
20673591
[PubMed - indexed for MEDLINE]
PMCID:
PMC2963687
Free PMC Article

Images from this publication.See all images (5)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk